ArticleFrontiers in pharmacology2026

Cost-utility analysis of add-on ezetimibe to moderate-intensity statin versus moderate-intensity statin alone for secondary prevention in patients with acute coronary syndrome intolerant to high-intensity statin therapy in Thailand.

Nattiwat Promchit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.